CN1348375A - 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 - Google Patents

用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 Download PDF

Info

Publication number
CN1348375A
CN1348375A CN00806738A CN00806738A CN1348375A CN 1348375 A CN1348375 A CN 1348375A CN 00806738 A CN00806738 A CN 00806738A CN 00806738 A CN00806738 A CN 00806738A CN 1348375 A CN1348375 A CN 1348375A
Authority
CN
China
Prior art keywords
disease
pharmaceutical composition
nerve
purposes
neural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00806738A
Other languages
English (en)
Chinese (zh)
Inventor
M·辛尼茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN1348375A publication Critical patent/CN1348375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN00806738A 1999-03-25 2000-03-24 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物 Pending CN1348375A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL129178 1999-03-25
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation

Publications (1)

Publication Number Publication Date
CN1348375A true CN1348375A (zh) 2002-05-08

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00806738A Pending CN1348375A (zh) 1999-03-25 2000-03-24 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物

Country Status (16)

Country Link
US (1) US6914056B1 (enExample)
EP (1) EP1162959B1 (enExample)
JP (1) JP2002540146A (enExample)
KR (1) KR20010112364A (enExample)
CN (1) CN1348375A (enExample)
AT (1) ATE290385T1 (enExample)
AU (1) AU768911B2 (enExample)
BR (1) BR0009296A (enExample)
CA (1) CA2368597A1 (enExample)
DE (1) DE60018554T2 (enExample)
HK (1) HK1042038A1 (enExample)
IL (1) IL129178A0 (enExample)
MX (1) MXPA01009650A (enExample)
NZ (1) NZ514525A (enExample)
RU (1) RU2247557C2 (enExample)
WO (1) WO2000057865A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272080A (zh) * 2009-01-09 2011-12-07 西格马-奥利奇有限公司 β磷酸甘油的合成方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253918T1 (de) 1999-12-08 2003-11-15 Centre Nat Rech Scient Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
EP1511483A4 (en) * 2002-03-27 2009-03-18 Smithkline Beecham Corp PROCESSING METHODS USING LXR MODULATORS
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
NZ571975A (en) * 2006-04-26 2011-04-29 Toyama Chemical Co Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising benzothiopene alkyl ether derivative or salt thereof
EP2098237B1 (en) * 2006-12-28 2012-08-29 Ochanomizu University Analgesic agent comprising cyclic phosphatidic acid derivative
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
JP6007264B2 (ja) 2013-01-28 2016-10-12 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
CA3007063A1 (en) * 2015-12-08 2017-06-15 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272080A (zh) * 2009-01-09 2011-12-07 西格马-奥利奇有限公司 β磷酸甘油的合成方法

Also Published As

Publication number Publication date
EP1162959B1 (en) 2005-03-09
US6914056B1 (en) 2005-07-05
IL129178A0 (en) 2000-02-17
DE60018554T2 (de) 2006-04-13
WO2000057865A3 (en) 2001-06-28
RU2247557C2 (ru) 2005-03-10
AU768911B2 (en) 2004-01-08
JP2002540146A (ja) 2002-11-26
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
BR0009296A (pt) 2001-12-18
WO2000057865A9 (en) 2001-11-15
EP1162959A2 (en) 2001-12-19
KR20010112364A (ko) 2001-12-20
AU3451700A (en) 2000-10-16
HK1042038A1 (zh) 2002-08-02
WO2000057865A2 (en) 2000-10-05
ATE290385T1 (de) 2005-03-15
DE60018554D1 (de) 2005-04-14
CA2368597A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
CN1348375A (zh) 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物
Longo et al. Action of nicotine and of the" ganglioplegiques centraux" on the electrical activity of the brain
EP1397105B1 (en) Compositions for inhibiting angiogenesis
Honda et al. Uridine as an active component of sleep-promoting substance: its effects on nocturnal sleep in rats
Osaka et al. Noradrenergic inputs to sleep-related neurons in the preoptic area from the locus coeruleus and the ventrolateral medulla in the rat
Hunter et al. Alcohol withdrawal syndrome in rats: Neural and behavioral correlates
Hosford et al. Neural network of structures in which GABAB receptors regulate absence seizures in the lethargic (lh/lh) mouse model
US8017597B2 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
Kofman et al. Intracerebroventricularmyo-inositol antagonizes lithium-induced suppression of rearing behaviour in rats
Kofler et al. A multidimensional approach in testing nootropic drug effects (Cerebrolysin®)
Pan et al. Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat
Millan et al. The involvement of excitatory amino acid receptors within the prepiriform cortex in pilocarpine-induced limbic seizures in rats
US20160354402A1 (en) Compositions
Brophy et al. Effects of scopolamine on the rewarding and seizure-inducing properties of amygdaloid stimulation
CN106668035A (zh) 一种抗癫痫药物组合物
Ninchoji et al. Effect of pinealectomy on cortically kindled rats
US20060040901A1 (en) Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants
Waddington et al. Characterisation of denervation supersensitivity in the striatonigral gam pathway of the kainic acil-lesioned rat and in huntington's disease
Szentivanyi et al. Studies on the hypothalamic regulation of histamine synthesis history and some current information
Yamada et al. The response to acoustic stimulation and the changes in brain amine levels after repeated administration of β-phenylethylamine in rats
Winsor Significance of the induced digital vasoconstrictor reflexes
Wick et al. The nature of the action of insulin
HK1171657A (en) Methods for treating or preventing fatigue
HK1234314A1 (en) Methods for treating or preventing fatigue

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication